Taking an active role in increasing the competitiveness of the national industry through research and sustainable technological innovation in the pharmaceutical sector, Dexa Laboratories of Biomolecular Sciences (DLBS) received the Rintisan Teknologi Industri 2021 award from the Ministry of Industry of the Republic of Indonesia. The award was handed over by the Minister of Industry of the Republic of Indonesia, Mr. Agus Gumiwang Kartasasmita, to the Commercial Director of PT Dexa Medica Mr. V. Hery Sutanto, in Jakarta, December 1, 2021.
According to the Minister of Industry of the Republic of Indonesia, Mr. Agus Gumiwang, the industry needs to carry out research activities and with the aim of developing technology so that our dependence on imports can be minimized.
“To become the top 10 countries with the world’s largest economies by 2030, Indonesia will become the center of the world economy in 2030. Of course, one of the ways we can achieve this mission is to encourage increased research and technology, especially those that will produce new technologies for industry. And more importantly, the industry’s contribution to GDP is still the highest,” explained Mr. Agus Gumiwang.
Executive Director of Dexa Laboratories of Biomolecular Sciences, Dr. Raymond Tjandrawinata added that research and innovation of products made from original Indonesian raw materials was carried out in Indonesia DLBS. DLBS is a research center for drug discovery and development that utilizes living things to improve human life. This effort is a step to encourage the independence of national medicinal raw materials while at the same time providing added value to the Indonesian economy because it empowers farmers to distributors.
“In the 2021 Industrial Technology Pilot event, DLBS carries the HerbaAsimor product which is an Indonesian scientific innovation product that is useful for increasing breast milk production. HerbaAsimor itself is made from torbangun leaves, katuk leaves, and cork fish. These three ingredients are used in the production process of Galatonol and Striatin which are all cultivated by Indonesian farmers. The Domestic Component Level (TKDN) of HerbaAsimor itself reached 81.09%,” said Mr. Raymond.
Besides being used in Indonesia, since May 2021, HerbaAsimor has also been exported to foreign countries, including the Philippines.
Meanwhile, according to Mr. V. Hery Sutanto, one of Dexa Medica’s roles as a pharmaceutical industry through Dexa Laboratories of Biomolecular Sciences (DLBS) is to support the government’s efforts to realize the independence of raw materials for medicines. This is because 95 percent of medicinal raw materials are still imported from India, China and Europe.
“We are actively innovating through modern research and technology to develop pharmaceutical products made from natural ingredients native to Indonesia. Currently, Dexa Group is one of the most active pharmaceutical companies in producing Marketing Permit Numbers or NIE Original Indonesian Modern Medicines or OMAI in Indonesia. Around 87 percent of NIE phytopharmaca is contributed by Dexa Group, meanwhile NIE for Standardized Herbal Medicines or OHT of about 26% is also produced by Dexa Group, “said Mr. V.Hery.